The financing round was led by Molten Ventures with backing from LifeX Ventures and private individuals.
"With our technology, we’re building the world’s largest immune data assets across health and disease, which allows us to perform analyses with a level of depth and granularity that was previously unthinkable. This systems-level approach to understanding immune function enables us to look at the bigger picture rather than just focusing on individual disease-associated parameters. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run."
— Adam Laing, President and Chief Scientific Officer
Plural led the Series A follow-on round to help the company scale its precision medicine platform and expand globally.
"Precision medicine is transforming how we think about and approach healthcare, and clinical trials are the bedrock of precision drug development. In the past 12 months, we’ve scaled up our capacity to hold three times more trials than the year before and launched our first programme supporting families affected by ALS. I’m so pleased with everything the team has achieved so far and this new funding will help us to integrate LLMs and other AI tools to drive more productivity. This will help us continue our growth trajectory, particularly with the help of visionary investors like Carina Namih, who supported our seed round and is now supporting us again at Plural."
The funding round was co-led by DSW Ventures and NG Bio alongside a grant from Innovate UK.
"We have been developing this method of treatment for a decade now, with support from Versus Arthritis, and it has proved successful in laboratory tests, but the funding will allow us to move toward human clinical trials."
The funding round was co-led by Clean Growth Fund and Pymwymic to support research and commercialisation.
"Intensive agriculture and overuse of agrochemicals have contributed to a 70% biodiversity loss in the past 50 years, which has been made worse by the damaging effects of climate change – drought, soil warming and higher levels of CO₂."
The funding round was led by Eos Advisory and includes participation from the Scottish National Investment Bank.
"This funding round marks an important milestone for Cumulus, as oncology remains a critical area of scientific innovation and unmet medical need. At Cumulus, we're not only innovating at the scientific level but also offering a uniquely differentiated process for decision-making and prioritisation in drug discovery and development. The business model enables only the strongest science to be translated from discovery into clinical trials. Our portfolio approach aims to enhance the ultimate success rate in cancer therapy development, which currently remains unacceptably low. It also provides an alternative approach to the de-risking of early-stage oncology investment. We are grateful for the support from Eos and the Scottish National Investment Bank enabling us to continue investing in our existing companies and expand our portfolio of new biotechs, advancing our mission to develop the next generation of cancer therapies."
